Description
Rydapt (Midostaurin) 25mg Online
Rydapt (Midostaurin) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing.
It is used to treat acute myelogenous leukemia and systemic mastocytosis. And also used to treat cancers such as leukemia, breast cancer, melanoma, lung cancer, and renal cancer. They are also used in the treatment of rheumatoid arthritis and to prevent organ transplant rejection. They work by stopping cancer cell growth and preventing the spread of the cells.
Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3 and KIT kinase. Midostaurin inhibits FLT3 receptor signalling and induces cell cycle arrest and apoptosis in leukaemic cells expressing FLT3 ITD or TKD mutant receptors or over-expressing FLT3 wild-type receptors. In vitro data indicate that midostaurin inhibits D816V mutant KIT receptors at exposure levels achieved in patients (average achieved exposure higher than IC50). In vitro data indicate that KIT wild-type receptors are inhibited to a much lesser extent at these concentrations (average achieved exposure lower than IC50). Midostaurin interferes with aberrant KIT D816V-mediated signaling and inhibits mast cell proliferation, survival, and histamine release.
In addition, midostaurin inhibits several other receptor tyrosine kinases such as PDGFR (platelet-derived growth factor receptor) or VEGFR2 (vascular endothelial growth factor receptor 2), as well as members of the serine/threonine kinase family PKC (protein kinase C). Midostaurin binds to the catalytic domain of these kinases and inhibits the mitogenic signalling of the respective growth factors in cells, resulting in growth arrest. Midostaurin in combination with chemotherapeutic agents (cytarabine, doxorubicin, idarubicin, and daunorubicin) resulted in synergistic growth inhibition in FLT3-ITD expressing AML cell lines.
